Trial Profile
Randomised phase II study of Gemcitabine (Gem) or Methotrexate and Vinblastine (Mv) in advanced transitional cell carcinoma of the urothelium.
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 17 Jun 2016
Price :
$35
*
At a glance
- Drugs Gemcitabine (Primary) ; Methotrexate; Vinblastine
- Indications Bladder cancer; Urogenital cancer
- Focus Therapeutic Use
- Sponsors Eli Lilly and Company
- 09 Nov 2009 New trial record